Muvalaplin (LY3473329) MAD in Healthy Japanese

Phase 1, randomised, double-blind trial in elevated lipoprotein(a) (Lp(a)) comparing LY3473329 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Day 43. Started Nov 2021; status: completed.